Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Investor Presentation (May 2026)
28 slides from Akari Therapeutics's investor presentation, May 2026
Slide 1: Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads
Corporate Presentation Advancing Antibody Drug Conjugates With May 2026 Novel Immuno-Oncology Payloads NASDAQ: AKTX akaritx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc
Slide 3: Senior Leadership Team Brings Deep Oncology/Biotech Experience
Senior Leadership Team Brings Deep Oncology/Biotech Experience Abizer Gaslightwala, MS, MBA Satyajit Mitra, PhD President, Chief Executive Officer Executive Director, Head of Oncology 25 years in the development and commercialization of Scientist with 20 years in advancing novel oncology programs no
Slide 4: Akari – A Radical Redesign to ADC Payloads - Opportunity To Drive Significant Value Quickly
Akari – A Radical Redesign to ADC Payloads - Opportunity To Drive Significant Value Quickly 1 2 3 PAYLOAD ACCELERATING NEAR-TERM INNOVATION LEAD PROGRAM VALUE PH1 Payload – Targeting RNA Splicing AKTX-101 – TROP2 ADC Near-Term Catalysts to Drive - Potent cytotoxicity - TROP2 is a validated target Si
Slide 5: Akari PH1 Payload Driving Multiple ADC Programs
Akari PH1 Payload Driving Multiple ADC Programs Lead Asset AKTX-101 Has Initiated IND Enabling Work ADC Programs Indication Discovery Preclinical IND Enabling Highlights (All PH1 Payload Based) - Initiated IND enabling activities - GLP tox data expected Q4 2026 Urothelial AKTX-101 Cancer; Other - Ph
Slide 6: AKTX-101 Path to Clinic: Projected IND/CTA Filing By Mid-2027
AKTX-101 Path to Clinic: Projected IND/CTA Filing By Mid-2027 Activity 2026 2027 IND / CTA GLP Toxicology / Non-clinical studies and Enabling Activities Manufacturing Scale-up (Pre-Clinical) IND/CTA Pre-IND Filing FIH Start - Timeline Consultation (IND / CTA) Dose Escalation WuXi AACR ASCO Data GLP
Slide 7: PH1 ADC Payload Background and AKTX-101 Opportunity and Timeline
o PH1 ADC Payload Background o AKTX-101 Opportunity and Timeline 7
Slide 8: Akari’s Unique Approach to ADCs – Targeting RNA Splicing to Attack Cancer
Akari’s Unique Approach to ADCs – Targeting RNA Splicing to Attack Cancer Antibody + Linker + Chemotherapy / Toxin (Targeted Cytotoxicity) Traditional ADC o Over 95% of payloads in current ADCs target tubulin or DNA Payload These payloads target processes essential only to dividing cancer cells or
Slide 9: PH1 Payload Has Several Competitive Advantages Relative To Current ADC Payloads
PH1 Payload Has Several Competitive Advantages Relative To Current ADC Payloads Attribute PH1 Payload Topo1 Inhibitors Microtubule Inhibitors Optimal Potency as a < 5 nanomolar IC50 5-20x nanomolar IC50 < 1 nanomolar IC50 Cytotoxic agent Susceptible to MDR No – payload not subject to this tumor Yes
Slide 10: Spliceosome Modulators Lock SF3B1 in Open Conformation
Spliceosome Modulators Lock SF3B1 in Open Conformation Splicing modulators prevent binding of Branch Point Acceptor (BPA) to SF3B1 Model of SF3B1 and PHF5α binding to intron BPA and location of resistance mutations PH1 is closely related to Thailanstatin A, Teng et al., 2017 Nat Comm Spliceostatin A
Slide 11: PH1’s Mechanism of Action is Uniquely Selected For Generating Mis-Spliced Transcripts
PH1’s Mechanism of Action is Uniquely Selected For Generating Mis-Spliced Transcripts Leading to Immunogenic Neo-Peptides 9x Greater than the payload DM4 of Mirvetuximab Soravtansine, shown in comparison below Average (n=4 wells) expression of spliced RNA transcripts showing effect of DM4 (L, tubuli
Slide 12: In Gastric Cancer, AKTX-101 Has Superior Anti-Tumor Activity Compared To Trodelvy in Preclinical Models
In Gastric Cancer, AKTX-101 Has Superior Anti-Tumor Activity Compared To Trodelvy® in Preclinical Models Tumor Volume (mm3) 750 Method NCI-N87 cell xenograft model Dosing regimen: Day 1 and Day 8 for both 500 AKTX-101 and Trodelvy® to align with approved dosing schedule for Trodelvy® Results 250 Sta
Slide 13: PH1 Payload Uniquely Activates Innate and Adaptive Immune System For Greater and Longer Efficacy
PH1 Payload Uniquely Activates Innate and Adaptive Immune System For Greater and Longer Efficacy(1) MC38-hHer2 Model Pro-Inflammatory Macrophages and Increase In Neutrophils vs Kadcyla® "Tras PH1" is Trastuzumab-PH1 ADC Expands B Cells and IgM Antibodies vs. Kadcyla® - IgM antibodies target cancer c
Slide 14: Trastuzumab-PH1 Exhibits Activity Alone and in Combination with mPD-1 in a Syngeneic Model
Trastuzumab-PH1 Exhibits Activity Alone and in Combination with mPD-1 in a Syngeneic Model Anti-Tumor Immunity ADC Treatment and Survival Curves Rechallenge Vehicle T-PH1 Kad 2000 2000 2000 MC38-hHer2 ADC Doses MC38 1500 1500 1500 1000 parental B16-F10 1000 1000 500 500 500 300 300 200 CR 300 200 CR
Slide 15: Lead Program AKTX-101 (TROP2 PH1 ADC)
Lead Program AKTX-101 (TROP2 PH1 ADC) 15
Slide 16: AKTX-101: Highly Differentiated TROP2 ADC With Novel PH1 Payload
AKTX-101: Highly Differentiated TROP2 ADC With Novel PH1 Payload Novel Antibody With Cell Killing Intact - Employs proprietary TROP2 antibody - Higher affinity than hRS7 (Sacituzumab) - Potent ADC action while mitigating ADA immunogenicity Reduced Off-Target Effects - AKTX-101 uses L22 lysine non- c
Slide 17: AKTX-101 Designed To Be Superior To Current TROP2 ADCs Across Both Key Efficacy and Safety Attributes
AKTX-101 Designed To Be Superior To Current TROP2 ADCs Across Both Key Efficacy and Safety Attributes Key Measure Trodelvy® (leading TROP2 ADC ) Akari AKTX-101* - 3 mg/ kg superior in Gastric Cancer in NCI-N87 - 10mg/ kg Tumor Potency - DAR 7.6 cell xenograft model - DAR 4.0 - Repolarization of Macr
Slide 18: AKTX-101 Has A Differentiated Safety Profile vs Current TROP2 ADCs
AKTX-101 Has A Differentiated Safety Profile vs Current TROP2 ADCs: No Neutropenia, Diarrhea, Mucositis, or Interstitial Lung Disease Observed Key Safety Warnings Of Approved TROP2 ADCs - Boxed warning for neutropenia or bone marrow suppression (Trodelvy®) - GI toxicities (Trodelvy®) - Lung toxicity
Slide 19: Urothelial Cancer is Part of a Larger Opportunity for AKTX-101, Based on Solid Tumors
Urothelial Cancer is Part of a Larger Opportunity for AKTX-101, Based on Solid Tumors That Have High TROP2 Expression Cancer Type New Annual Cases Annual Deaths Initial Target: Urothelial Cancer 85,000 17,000 Breast 319,750 42,680 Lung 226,650 124,730 Colorectal 154,270 52,900 Head and Neck 72,680 1
Slide 20: In Urothelial Cancer, 2nd Line Opportunity Is Valuable and Makes an Attractive Strategic Entry Point
In Urothelial Cancer, 2nd Line Opportunity Is Valuable and Makes an Attractive Strategic Entry Point For AKTX-101 DIAGNOSIS: metastatic Urothelial Carcinoma (mUC) PREFERRED 1ST LINE THERAPY (Standard of Care for All-Comers) + Enfortumab Vedotin + Pembrolizumab (Regardless of Cisplatin Eligibility) D
Slide 21: First-in-Human Phase 1a Trial Explores Safety, Therapeutic Dose, And Identifies Efficacy Signals
se 1a Trial Explores Safety, Therapeutic Dose, And Identifies Efficacy Signals In Range of Solid Tumors n Into Urothelial Cancer Drives Potential Accelerated Path First-in-Human Phase 1a Trial Explores Safety, Therapeutic Dose, And Identifies Efficacy Signals In Range of Solid Tumors Phase 1b Expans
Slide 22: Akari and WuXi XDC Strategic Partnership Demonstrates WuXi’s Continued Investment Into ADC Payload Innovation
Akari and WuXi XDC Strategic Partnership Demonstrates WuXi’s Continued Investment Into ADC Payload Innovation Beyond Just a Traditional CDMO Agreement Global Leader in ADC Strategic Partnership Advances Innovation In Addition To Akari’s Novel PH1 payload for Development & Manufacturing AKTX-101 and
Slide 23: ADCs Driving Significant Deal Flow Highlights Strong Industry Demand
ADCs Driving Significant Deal Flow Highlights Strong Industry Demand for Next-Generation ADC Technologies Recent Landmark ADC Transactions $300 Million $5 Billion $2.5 Billion Up to Up to Preclinical TROP2- targeting TOP1i/ATRi dual-payload ADC acquired by acquired by acquired by April 14, 2026 Apri
Slide 24: Akari’s Value Today Offers The Potential For Large Upside by FIH data
Akari’s Value Today Offers The Potential For Large Upside by FIH data Based On Comparable ADC Peers 1,500 Valuation / Market Cap At Stage ($M) 1,000 $M >13X ~1.0B Mkt Cap Today (4) 500 Post-Data $285M Total Deal Size Post-Data >6X Akari Today 0 Pre-Clinical $44M Mkt Cap ~$75M Mkt Cap ADC Companies1
Slide 25: Akari Cap Table And Cash
Akari Cap Table And Cash Capitalization (As of March 31, 2026) Shares outstanding (ADS Equivalents) Common Stock 1,144,587 Prefunded Warrants 344,120 As Exercised (ADS's + pre-funded warrants) 1,488,707 Warrants (WAEP $92.08) 1,336,869 Stock Options (WAEP $87.97) 156,118 Convertible Notes 22,901 Sub
Slide 26: Akari Is Advancing Novel Payloads With AKTX-101 - Reaching Clinical Milestones and Multiple Value Inflections
Akari Is Advancing Novel Payloads With AKTX-101- Reaching Clinical Milestones and Multiple Value Inflections Through Next 18 Months Radical Redesign of ADC Payloads To Transform Category • PH1 Payload – Uniquely Targeting RNA Splicing • Potent cytotoxicity • Novel immune activation: innate and adapt
Slide 27: Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads
Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads
Slide 28: Supplemental Corporate Information
Supplemental Corporate Information: Akari Website: https://akaritx.com Recent Press Releases: 1. Akari Therapeutics Secures Australian Patent Approval 2. ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors 3. Akari Therapeutics Announces Strategic Partnership w
Akari Therapeutics — Investor Presentation (May 2026) on 6ix